Mon, April 18, 2011
[ Mon, Apr 18th 2011 ] - Market Wire
00 a.m. ET
Sun, April 17, 2011
Fri, April 15, 2011
Thu, April 14, 2011
Wed, April 13, 2011
Tue, April 12, 2011
Mon, April 11, 2011
Sun, April 10, 2011
Sat, April 9, 2011
Fri, April 8, 2011
Thu, April 7, 2011
[ Thu, Apr 07th 2011 ] - Market Wire
Volunteering Does a Body Good
Wed, April 6, 2011
Tue, April 5, 2011
Mon, April 4, 2011
Sun, April 3, 2011
Sat, April 2, 2011
Fri, April 1, 2011
Thu, March 31, 2011
Wed, March 30, 2011
Tue, March 29, 2011

30 a.m. Eastern Time Monday, April 11 to Discuss Phase 3 Trial Results for Dimebon in Huntington Disease


//health-fitness.news-articles.net/content/2011/ .. l-results-for-dimebon-in-huntington-disease.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


SAN FRANCISCO, CA--(Marketwire - April 8, 2011) - Medivation, Inc. (NASDAQ: [ MDVN ]) today announced that it will hold a teleconference and webcast at 8:30 a.m. Eastern Time, Monday, April 11, to discuss the HORIZON Phase 3 trial results for dimebon (latrepirdine) in patients with Huntington disease. A press release will be issued at 7:30 a.m. Eastern Time Monday prior to this call.

Teleconference/Webcast Details

To participate in the live call on Monday, April 11, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time), please dial 866-582-8907 for domestic callers and +1-678-825-8232 for international callers. In addition, the live conference call is being webcast and can be accessed on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at [ www.medivation.com ]. A replay also will be available for 30 days following the live call.

About Medivation
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partners Astellas and Pfizer, Medivation currently has investigational drugs in Phase 3 development to treat advanced prostate cancer, mild-to-moderate Alzheimer's disease and Huntington disease. For more information, please visit us at [ www.medivation.com ].


Publication Contributing Sources